Ramipril modulates circadian gene expression in skeletal muscle
Treatment with angiotensin converting enzyme (ACE)-inhibitors favorably affects glucose metabolism and the development of diabetes mellitus by largely elusive mechanisms. To identify these mechanisms, we studied the effect of ACE-inhibition on gene expression in skeletal muscle, a primary target tis...
Saved in:
Published in | Pharmacogenetics and genomics Vol. 21; no. 11; p. 751 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.11.2011
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Treatment with angiotensin converting enzyme (ACE)-inhibitors favorably affects glucose metabolism and the development of diabetes mellitus by largely elusive mechanisms. To identify these mechanisms, we studied the effect of ACE-inhibition on gene expression in skeletal muscle, a primary target tissue for insulin in glucose homeostasis.
A subject-blinded and analyst-blinded, placebo-controlled study was conducted in nine healthy men. Two consecutive muscle biopsies were conducted before and 9 h after a single dose of either 10-mg ramipril (n=6) or placebo (n=3), (randomly allocated). Muscle ribonucleic acid was subjected to transcriptome profiling.
In both ramipril-treated or placebo-treated individuals, the majority of genes with differential expression between the two time points belonged to the family of diurnally regulated genes, such as the NR1D1 and NR1D2 genes (nuclear receptor subfamily 1, group D, members 1 and 2) or members of the period homolog family (PER1-3). Ramipril significantly modulated the expression of other diurnally regulated genes, such as aryl hydrocarbon receptor nuclear translocator-like (ARNTL), encoding aryl hydrocarbon receptor nuclear translocator-like, a core component of the circadian clock (P=0.02). Concomitant attenuation of NR1D1 downregulation (-2.4-fold compared with -4.1-fold in placebo; P=0.04), a transcriptional repressor of ARNTL, supported the view that ramipril might modulate glucose homeostasis pathways involving the NR1D1 ARNTL axis.
As circadian rhythms are deranged in patients who are diabetic, modulated expression of circadian clock genes by ramipril could explain the favorable metabolic effects of therapeutic ACE-inhibition. |
---|---|
AbstractList | Treatment with angiotensin converting enzyme (ACE)-inhibitors favorably affects glucose metabolism and the development of diabetes mellitus by largely elusive mechanisms. To identify these mechanisms, we studied the effect of ACE-inhibition on gene expression in skeletal muscle, a primary target tissue for insulin in glucose homeostasis.
A subject-blinded and analyst-blinded, placebo-controlled study was conducted in nine healthy men. Two consecutive muscle biopsies were conducted before and 9 h after a single dose of either 10-mg ramipril (n=6) or placebo (n=3), (randomly allocated). Muscle ribonucleic acid was subjected to transcriptome profiling.
In both ramipril-treated or placebo-treated individuals, the majority of genes with differential expression between the two time points belonged to the family of diurnally regulated genes, such as the NR1D1 and NR1D2 genes (nuclear receptor subfamily 1, group D, members 1 and 2) or members of the period homolog family (PER1-3). Ramipril significantly modulated the expression of other diurnally regulated genes, such as aryl hydrocarbon receptor nuclear translocator-like (ARNTL), encoding aryl hydrocarbon receptor nuclear translocator-like, a core component of the circadian clock (P=0.02). Concomitant attenuation of NR1D1 downregulation (-2.4-fold compared with -4.1-fold in placebo; P=0.04), a transcriptional repressor of ARNTL, supported the view that ramipril might modulate glucose homeostasis pathways involving the NR1D1 ARNTL axis.
As circadian rhythms are deranged in patients who are diabetic, modulated expression of circadian clock genes by ramipril could explain the favorable metabolic effects of therapeutic ACE-inhibition. |
Author | Krebs, Michael Brunner, Martin Sauermann, Robert Schmidt, Wolfgang M Müller, Markus |
Author_xml | – sequence: 1 givenname: Robert surname: Sauermann fullname: Sauermann, Robert organization: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria – sequence: 2 givenname: Wolfgang M surname: Schmidt fullname: Schmidt, Wolfgang M – sequence: 3 givenname: Michael surname: Krebs fullname: Krebs, Michael – sequence: 4 givenname: Martin surname: Brunner fullname: Brunner, Martin – sequence: 5 givenname: Markus surname: Müller fullname: Müller, Markus |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21881539$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j9tKxDAURYMozkX_QCQ_0DEn9z6JFEeFAUX0ecgkJxJt09JMQf9-BtSn_bJYrL0gp7nPSMgVsBWw2tysX5oV2zEQKLgV0lnN4YTMwUhZaWvZjCxK-WRM6FryczLjYC0oUc_J7avr0jCmlnZ9mFq3x0J9Gr0LyWX6gRkpfg8jlpL6TFOm5Qtb3LsjPxXf4gU5i64tePm3S_K-vn9rHqvN88NTc7epvLAKKu-d2tVYK4MSpNMaYozeWa6Ul6BMgBgCqIiBOW9sCMYbHS2zUSrGNOdLcv3rHaZdh2F7TO7c-LP9f8IP1WRM6Q |
CitedBy_id | crossref_primary_10_1016_j_regpep_2013_06_016 crossref_primary_10_3390_ijms19082418 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1097/FPC.0b013e32834a8621 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1744-6880 |
ExternalDocumentID | 21881539 |
Genre | Randomized Controlled Trial Journal Article |
GroupedDBID | --- .Z2 0R~ 123 4Q1 4Q2 4Q3 53G 5VS 8L- AAAAV AAHPQ AAIQE AAMTA AARTV AASCR AAYOK ABASU ABBUW ABDIG ABJNI ABVCZ ABXVJ ABZAD ACDDN ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFDTB AFUWQ AHQNM AHRYX AHVBC AINUH AJIOK AJNWD AJNYG AJZMW ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BQLVK C45 CGR CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F2K F2L F5P FCALG FL- GNXGY GQDEL HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 KD2 KMI L-C NPM O9- OAG OAH OCUKA OJAPA OL1 OLV OLW OLZ OPC OPUJH ORVUJ OUVQU OVD OVDNE OWU OWV OXXIT P2P RIG RLZ S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W ZFV ZZMQN |
ID | FETCH-LOGICAL-c3851-cca5b9e957e414a661fffca8255c4157d1fdd15fed0ac78dd7c76f808f4500622 |
IngestDate | Sat Sep 28 07:48:35 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3851-cca5b9e957e414a661fffca8255c4157d1fdd15fed0ac78dd7c76f808f4500622 |
PMID | 21881539 |
ParticipantIDs | pubmed_primary_21881539 |
PublicationCentury | 2000 |
PublicationDate | 2011-November |
PublicationDateYYYYMMDD | 2011-11-01 |
PublicationDate_xml | – month: 11 year: 2011 text: 2011-November |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Pharmacogenetics and genomics |
PublicationTitleAlternate | Pharmacogenet Genomics |
PublicationYear | 2011 |
SSID | ssj0036942 |
Score | 2.0545895 |
Snippet | Treatment with angiotensin converting enzyme (ACE)-inhibitors favorably affects glucose metabolism and the development of diabetes mellitus by largely elusive... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 751 |
SubjectTerms | Adolescent Adult Angiotensin-Converting Enzyme Inhibitors - administration & dosage Angiotensin-Converting Enzyme Inhibitors - pharmacology Circadian Rhythm - drug effects Circadian Rhythm - genetics Gene Expression Profiling Gene Expression Regulation - drug effects Humans Male Middle Aged Muscle, Skeletal - drug effects Muscle, Skeletal - metabolism Placebos Ramipril - administration & dosage Ramipril - pharmacology Real-Time Polymerase Chain Reaction RNA, Messenger - genetics RNA, Messenger - metabolism Young Adult |
Title | Ramipril modulates circadian gene expression in skeletal muscle |
URI | https://www.ncbi.nlm.nih.gov/pubmed/21881539 |
Volume | 21 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwELYKe-GCYB88d-XDiss2QIPjxwmhahHalVAFregNOY4NESRUDRUqv55xHCelFO3jElVxY0WZL-PPk5lvEPoujGZUEx1EJmQBkSENRByJQAM3okww-6XPZluc07MB-TWMhq3W02x1yWO8r54X1pX8j1XhHNjVVsn-g2XrSeEE_Ab7whEsDMe_svGFzNLROL23_WxsGy5d_FDpWDm5AbhKWwF_l-haJjQWd7DI2OrHbFL4qSpi2qskrO1VtXKzFXDNZtLhL-XEOnJHeV1OdvMh5zZLk9KjXz3cmxuZ3zSB1t9jHRfzSfplDGDiO385OYPZGIRNgqtjENr5TUZIQLlryuQdqyt99gDqzLhJ5kRm37hvJwt82uv6-CyQHyJh0_Xq72CEUVaaFPgJB5ct_jw6J6rth5bQEuPWMZ7bII9bwI-oIKGvshTsYNHtlBrSboq5_UjJS_praLXaUOATh4511NL5R7RXmXPaxv2mwK5o4z3ca7TKp5_QsYcQriGEawhhCwbcQAinOfYQwg5Cn9Hg9Ge_exZUPTUCdQTkOoAXNoqFFhHTpEMksDNjjJIcdpYKuBxLOiZJOpHRyaFUjCcJU4wafsgNiWy9bfgFLecPud5EmBpjxSE5rJAxMYpLBRMrarSKWRiTZAttuAdzPXLCKdf-kW2_O7KDVhp87aIPBt5U_RVo32P8rTTSC7nWWn0 |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ramipril+modulates+circadian+gene+expression+in+skeletal+muscle&rft.jtitle=Pharmacogenetics+and+genomics&rft.au=Sauermann%2C+Robert&rft.au=Schmidt%2C+Wolfgang+M&rft.au=Krebs%2C+Michael&rft.au=Brunner%2C+Martin&rft.date=2011-11-01&rft.eissn=1744-6880&rft.volume=21&rft.issue=11&rft.spage=751&rft_id=info:doi/10.1097%2FFPC.0b013e32834a8621&rft_id=info%3Apmid%2F21881539&rft_id=info%3Apmid%2F21881539&rft.externalDocID=21881539 |